摘要
目的探讨宫颈癌患者血清S100钙离子结合蛋白A14(S100A14)和赖氨酰氧化酶样蛋白2(LOXL2)的表达水平及临床意义。方法选取2019年9月至2021年6月该院治疗的84例宫颈癌患者(宫颈癌组)、90例宫颈上皮瘤变患者(宫颈上皮瘤变组)以及同期在该院健康体检的80例健康女性(健康对照组)。用酶联免疫吸附试验(ELISA)检测血清S100A14和LOXL2的表达水平。绘制受试者工作特征(ROC)曲线,分析血清S100A14和LOXL2诊断及鉴别诊断宫颈癌的价值,计算曲线下面积(AUC)。分析血清S100A14、LOXL2表达水平与宫颈癌临床病理特征的关系。结果宫颈癌组血清S100A14和LOXL2表达水平均高于宫颈上皮瘤变组及健康对照组,差异有统计学意义(P<0.05),宫颈上皮瘤变组血清S100A14和LOXL2表达水平均高于健康对照组,差异有统计学意义(P<0.05)。血清S100A14、LOXL2诊断宫颈癌的AUC分别为0.895和0.929,鉴别诊断宫颈癌的AUC分别为0.744和0.833。宫颈癌患者血清S100A14与LOXL2呈正相关(r=0.239,P<0.05)。TNM分期为Ⅲ~Ⅳ期、高分化、肿瘤最大径≥4 cm、浸润深度≥1/2肌层、淋巴结转移宫颈癌患者的血清S100A14、LOXL2表达水平均高于TNM分期为Ⅰ~Ⅱ期、中低分化、肿瘤最大径<4 cm、浸润深度<1/2肌层、淋巴结未转移宫颈癌患者(P<0.05)。血清S100A14、LOXL2分别与宫颈癌TNM分期呈正相关(P<0.05)。结论血清S100A14和LOXL2对宫颈癌的早期诊断及病情评估有一定价值。
Objective To explore the expression and clinical significance of serum S100 calcium-binding protein A14(S100A14)and lysyl oxidase-like protein 2(LOXL2)in patients with cervical cancer.Methods A total of 84 patients with cervical cancer(cervical cancer group),90 patients with cervical epithelial neoplasia(cervical epithelial neoplasia group),and 80 healthy women(healthy control group)admitted in the hospital from September 2019 to June 2021 were selected.Enzyme-linked immunosorbent assay(ELISA)was used to detect the expression levels of serum S100A14 and LOXL2.Receiver operating characteristic(ROC)curve was drawn,the value of serum S100A14 and LOXL2 in the diagnosis and differential diagnosis of cervical cancer was analyzed,and the area under the curve(AUC)was calculated.The relationship between expression levels of serum S100A14,LOXL2 and clinicopathological characteristics of cervical cancer was analyzed.Results The expression levels of serum S100A14 and LOXL2 in cervical cancer group were higher than those in cervical epithelial neoplasia group and healthy control group,and the differences were statistically significant(P<0.05).The expression levels of serum S100A14 and LOXL2 in cervical neoplasia group were higher than those in healthy control group,and the differences were statistically significant(P<0.05).The AUC of serum S100A14 and LOXL2 for diagnosis of cervical cancer were 0.895 and 0.929,respectively.The AUC of serum S100A14 and LOXL2 for differential diagnosis of cervical cancer were 0.744 and 0.833,respectively.Serum S100A14 and LOXL2 in patients with cervical cancer were positively correlated(r=0.239,P<0.05).The expression levels of serum S100A14 and LOXL2 of cervical cancer patients with TNM stageⅢ—Ⅳ,well differentiated,tumor diameter≥4 cm,infiltration depth≥1/2 muscle layer,lymph node metastasis were higher than those of cervical cancer patients with TNM stagesⅠ—Ⅱ,moderately and poorly differentiated,tumor diameter<4 cm,infiltration depth<1/2 muscle layer,without lymph node metastasis(P<0.05).Serum S100A14 and LOXL2 were positively correlated with TNM stage of cervical cancer(P<0.05).Conclusion Serum S100A14 and LOXL2 have a certain value in the early diagnosis and disease assessment of cervical cancer.
作者
李彦英
黄平
张治
肖喜云
张玲
刘丹彤
LI Yanying;HUANG Ping;ZHANG Zhi;XIAO Xiyun;ZHANG Ling;LIU Dantong(Division.1 Department of Gynecology,Cangzhou Central Hospital,Cangzhou,Hebei 060000,China)
出处
《国际检验医学杂志》
CAS
2023年第1期40-43,48,共5页
International Journal of Laboratory Medicine
基金
沧州市重点研发计划指导项目(183302053)。
